Alecensa (alectinib capsules – Genentech) — Cigna

Initial criteria

• Patient age ≥ 18 years
• Patient has anaplastic lymphoma kinase (ALK)-positive disease
• Patient meets ONE of the following: patient has advanced, recurrent, or metastatic disease OR tumor is inoperable

Approval duration

1 year